Close Menu
Home » FDA Authorizes Adaptive Biotechnologies NGS Test for Minimal Residual Disease

FDA Authorizes Adaptive Biotechnologies NGS Test for Minimal Residual Disease

Oct 01, 2018
|
staff reporter

NEW YORK (GenomeWeb) — The US Food and Drug Administration on Friday granted de novo premarket authorization to Seattle-based Adaptive Biotechnologies' ClonoSeq, a next-generation sequencing test for measuring minimal residual disease (MRD) in acute lymphoblastic leukemia or multiple myeloma patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

After Your Number

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Not Quite How It Works

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Research, But Not in Name

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

Science Finds Support for Gene Drives Depends on Species Targeted, Ability to Control Drive; More

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Applied BioCode Submits Respiratory Pathogen Panel to FDA

  2. LumaCyte Obtains CE Mark for Cellular Analysis Platform

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.